Preclinical Evaluation of a Novel High-Affinity Radioligand [ 99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA)
| Parent link: | International Journal of Molecular Sciences.— .— Basel: MDPI AG Vol. 24 - iss.24.— 2023.— Article number 17391, 24p. |
|---|---|
| Övriga upphovsmän: | , , , , , , , , |
| Sammanfattning: | Radionuclide imaging using radiolabeled inhibitors of prostate-specific membrane antigen (PSMA) can be used for the staging of prostate cancer. Previously, we optimized the Glu-urea-Lys binding moiety using a linker structure containing 2-napththyl-L-alanine and L-tyrosine. We have now designed a molecule that contains mercaptoacetyl–triglutamate chelator for labeling with Tc99m (designated as BQ0413). The purpose of this study was to evaluate the imaging properties of [99mTc]Tc-BQ0413. PSMA-transfected PC3-pip cells were used to evaluate the specificity and affinity of [99mTc]Tc-BQ0413 binding in vitro. PC3-pip tumor-bearing BALB/C nu/nu mice were used as an in vivo model. [99mTc]Tc-BQ0413 bound specifically to PC3-pip cells with an affinity of 33 ± 15 pM. In tumor-bearing mice, the tumor uptake of [99mTc]Tc-BQ0413 (38 ± 6 %IA/g in PC3-pip 3 h after the injection of 40 pmol) was dependent on PSMA expression (3 ± 2 %IA/g and 0.9 ± 0.3 %IA/g in PSMA-negative PC-3 and SKOV-3 tumors, respectively). We show that both unlabeled BQ0413 and the commonly used binder PSMA-11 enable the blocking of [99mTc]Tc-BQ0413 uptake in normal PSMA-expressing tissues without blocking the uptake in tumors. This resulted in an appreciable increase in tumor-to-organ ratios. At the same injected mass (5 nmol), the use of BQ0413 was more efficient in suppressing renal uptake than the use of PSMA-11. In conclusion, [99mTc]Tc-BQ0413 is a promising probe for the visualization of PSMA-positive lesions using single-photon emission computed tomography (SPECT). Текстовый файл |
| Språk: | engelska |
| Publicerad: |
2023
|
| Ämnen: | |
| Länkar: | https://doi.org/10.3390/ijms242417391 http://apex.tpu.ru/ap/PUBLIKACIYA.ORIGINAL_PUBL1?p_image_id=113631&p_session_id=109393972742875 |
| Materialtyp: | Elektronisk Bokavsnitt |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=672736 |
MARC
| LEADER | 00000naa0a2200000 4500 | ||
|---|---|---|---|
| 001 | 672736 | ||
| 005 | 20251114153752.0 | ||
| 014 | |2 sici | ||
| 090 | |a 672736 | ||
| 100 | |a 20240527d2023 k||y0rusy50 ca | ||
| 101 | 1 | |a eng |c rus | |
| 102 | |a CH | ||
| 135 | |a drcn ---uucaa | ||
| 181 | 0 | |a a |b e | |
| 182 | 0 | |a b | |
| 183 | 0 | |a cr |2 RDAcarrier | |
| 200 | 1 | |a Preclinical Evaluation of a Novel High-Affinity Radioligand [ 99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA) |f E. Bezverkhniaia, P. Kanellopoulos, A. Abouzayed [et al.] |d Доклиническая оценка нового высокоаффинного радиолиганда [99mTc] Tc-BQ0413, нацеленного на простатспецифический мембранный антиген (PSMA) |z rus | |
| 203 | |a Текст |b визуальный |c электронный | ||
| 283 | |a online_resource |2 RDAcarrier | ||
| 320 | |a References: p. 22-24 (46 tit.) | ||
| 330 | |a Radionuclide imaging using radiolabeled inhibitors of prostate-specific membrane antigen (PSMA) can be used for the staging of prostate cancer. Previously, we optimized the Glu-urea-Lys binding moiety using a linker structure containing 2-napththyl-L-alanine and L-tyrosine. We have now designed a molecule that contains mercaptoacetyl–triglutamate chelator for labeling with Tc99m (designated as BQ0413). The purpose of this study was to evaluate the imaging properties of [99mTc]Tc-BQ0413. PSMA-transfected PC3-pip cells were used to evaluate the specificity and affinity of [99mTc]Tc-BQ0413 binding in vitro. PC3-pip tumor-bearing BALB/C nu/nu mice were used as an in vivo model. [99mTc]Tc-BQ0413 bound specifically to PC3-pip cells with an affinity of 33 ± 15 pM. In tumor-bearing mice, the tumor uptake of [99mTc]Tc-BQ0413 (38 ± 6 %IA/g in PC3-pip 3 h after the injection of 40 pmol) was dependent on PSMA expression (3 ± 2 %IA/g and 0.9 ± 0.3 %IA/g in PSMA-negative PC-3 and SKOV-3 tumors, respectively). We show that both unlabeled BQ0413 and the commonly used binder PSMA-11 enable the blocking of [99mTc]Tc-BQ0413 uptake in normal PSMA-expressing tissues without blocking the uptake in tumors. This resulted in an appreciable increase in tumor-to-organ ratios. At the same injected mass (5 nmol), the use of BQ0413 was more efficient in suppressing renal uptake than the use of PSMA-11. In conclusion, [99mTc]Tc-BQ0413 is a promising probe for the visualization of PSMA-positive lesions using single-photon emission computed tomography (SPECT). | ||
| 336 | |a Текстовый файл | ||
| 461 | 1 | |c Basel |n MDPI AG |t International Journal of Molecular Sciences | |
| 463 | 1 | |d 2023 |t Vol. 24 - iss.24 |v Article number 17391, 24p. | |
| 610 | 1 | |a prostate cancer | |
| 610 | 1 | |a prostate-specific membrane antigen | |
| 610 | 1 | |a PSMA | |
| 610 | 1 | |a technetium-99m | |
| 610 | 1 | |a BQ0413 | |
| 610 | 1 | |a single-photon emission computed tomography | |
| 610 | 1 | |a труды учёных ТПУ | |
| 610 | 1 | |a электронный ресурс | |
| 701 | 1 | |a Bezverkhniaia |b E. A. |c pharmacist |c Research Engineer Tomsk Polytechnic University |f 1994- |g Ekaterina Aleksandrovna |9 22467 | |
| 701 | 1 | |a Kanellopoulos |b P. |g Panagiotis | |
| 701 | 1 | |a Abouzayed |b A. |g Ayman | |
| 701 | 1 | |a Larkina |b M. S. |g Mariya Sergeevna |f 1984- |c pharmacist |c Professor; Senior Researcher of the Tomsk Polytechnic University, Doctor of Pharmaceutical Sciences |9 22417 | |
| 701 | 1 | |a Oroujeni |b M. |g Maryam | |
| 701 | 1 | |a Vorobjeva (Vorobyeva) |b A. G. |c specialist in the field of medical technology |c Senior Researcher, Oncoteranostika Research Center, Tomsk Polytechnic University, Ph.D |f 1990- |g Anzhelika Grigorjevna |9 22214 | |
| 701 | 1 | |a Rosenstrom |b U. |g Ulrika | |
| 701 | 1 | |a Tolmachev |b V. M. |c specialist in the field of medical technology |c Director of the Research Center "Oncoteranostika", Tomsk Polytechnic University, Ph.D |f 1961- |g Vladimir Maksimilianovich |9 22210 | |
| 701 | 1 | |a Orlova |b A. M. |c specialist in the field of medical technology |c Senior Researcher, Oncoteranostika Research Center, Tomsk Polytechnic University, Ph.D |f 1960- |g Anna Markovna |9 22212 | |
| 801 | 0 | |a RU |b 63413507 |c 20240527 | |
| 850 | |a 63413507 | ||
| 856 | 4 | |u https://doi.org/10.3390/ijms242417391 |z https://doi.org/10.3390/ijms242417391 | |
| 856 | 4 | |u http://apex.tpu.ru/ap/PUBLIKACIYA.ORIGINAL_PUBL1?p_image_id=113631&p_session_id=109393972742875 |z http://apex.tpu.ru/ap/PUBLIKACIYA.ORIGINAL_PUBL1?p_image_id=113631&p_session_id=109393972742875 | |
| 942 | |c CF | ||